Clinical Trial Update: Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

View source ↗

Summary

Post-authorization safety study evaluating empagliflozin in Type 2 diabetes patients in Saudi Arabia, focusing on ketoacidosis, severe urinary tract infection c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED | Results posted: 2022-02-10